相关实验视频

Updated: Jun 22, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

针对阿尔茨海默氏症和帕金森病的药物开发:我们现在走向何方?

Lisa Sequeira¹, Sofia Benfeito¹, Carlos Fernandes¹

¹CIQUP-IMS-Centro de Investigação em Química da Universidade do Porto, Institute of Molecular Sciences, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, R. Campo Alegre s/n, 4169-007 Porto, Portugal.

|June 27, 2024

概括

像阿尔茨海默氏症和帕金森症这样的神经退行性疾病缺乏修改疾病的治疗方法. 研究正在探索针对氧化应激和腺A2A受体的新药,以阻止疾病的进展.

科学领域:

神经学神经学
药理学药理学是指药理学的学科.
生物医学研究生物医学研究

背景情况:

神经退行性疾病 (NDs) 涉及渐进的神经元损失,影响认知和运动功能.
阿尔茨海默病 (AD) 和帕金森病 (PD) 是常见的,昂贵的ND,治疗选择有限.
目前的AD和PD治疗只能提供暂时的症状缓解,无法改变疾病的进展.

研究的目的:

为了回顾AD和PD的标志性特征.
总结目前针对AD和PD的药理疗法.
探索新型的治疗策略,用于NDs的疾病修饰.

主要方法:

对ND特征和现有治疗方法的文献综述.
对治疗AD和PD的药物开发研究趋势的分析.
对向氧化应激和腺A2A受体的候选药物的检查.

主要成果:

由于缺乏疾病修饰药物,AD和PD的重大负担.
现有的疗法只提供息治疗.
新兴的候选药物在向关键疾病途径方面表现有前途.

结论:

开发用于AD和PD的疾病修饰药物是一个至关重要的未满足的需求.
准氧化应激和腺A2A受体是一个有希望的途径.
进一步的研究对于将这些发现转化为有效的治疗方法至关重要.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.帕金森病是帕金森氏症的一种疾病.疾病修饰药物疾病修饰药物发现药物的发现.神经退行性疾病的神经退行性疾病

更多相关视频

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons

Published on: July 7, 2023

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...